PL3534904T3 - Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego - Google Patents

Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego

Info

Publication number
PL3534904T3
PL3534904T3 PL17803774.3T PL17803774T PL3534904T3 PL 3534904 T3 PL3534904 T3 PL 3534904T3 PL 17803774 T PL17803774 T PL 17803774T PL 3534904 T3 PL3534904 T3 PL 3534904T3
Authority
PL
Poland
Prior art keywords
phthalazinedione
dihydro
amino
treatment
multiple sclerosis
Prior art date
Application number
PL17803774.3T
Other languages
English (en)
Inventor
Wolfgang Brysch
Astrid Kaiser
Claudia VAN LAAK
Beate Ludescher
Maliha SHAH
Jörg VON WEGERER
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of PL3534904T3 publication Critical patent/PL3534904T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17803774.3T 2016-11-07 2017-11-06 Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego PL3534904T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16002355 2016-11-07
PCT/EP2017/001284 WO2018082814A1 (en) 2016-11-07 2017-11-06 Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Publications (1)

Publication Number Publication Date
PL3534904T3 true PL3534904T3 (pl) 2022-07-18

Family

ID=57249636

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17803774.3T PL3534904T3 (pl) 2016-11-07 2017-11-06 Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego

Country Status (7)

Country Link
US (1) US11007192B2 (pl)
EP (1) EP3534904B1 (pl)
CA (1) CA3042956A1 (pl)
DK (1) DK3534904T3 (pl)
ES (1) ES2918548T3 (pl)
PL (1) PL3534904T3 (pl)
WO (1) WO2018082814A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210161890A1 (en) * 2015-12-31 2021-06-03 Bach Pharma, Inc. Compositions and methods for treating brain dysfunction
WO2020117151A2 (en) 2018-06-21 2020-06-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising fingolimod and modafinil
WO2019245512A2 (en) 2018-06-21 2019-12-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising fingolimod and at least one anti-epileptic agent
TR201818859A2 (tr) * 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon
TR201819202A2 (tr) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon
TR201819197A2 (tr) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r multi̇pl skleroz ajani ve en az bi̇r anti̇-epi̇lepti̇k ajan i̇çeren bi̇r kombi̇nasyon
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
US20200215149A1 (en) * 2019-01-08 2020-07-09 Christopher David Thompson N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same
EP3858358A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
ES3057259T3 (en) 2020-03-25 2026-02-27 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
ES3057264T3 (en) 2020-06-10 2026-02-27 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
CN115916258A (zh) * 2020-07-09 2023-04-04 麦翠奥制药公司 糖皮质激素减量剂
EP4243602A4 (en) * 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022117221A1 (en) 2020-12-02 2022-06-09 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester
EP4483879A1 (en) 2023-06-29 2025-01-01 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
WO2025067689A1 (en) 2023-09-26 2025-04-03 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CN102971300B (zh) 2010-03-01 2016-03-02 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法
CA2829755A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
US10258620B2 (en) * 2014-12-18 2019-04-16 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form

Also Published As

Publication number Publication date
CA3042956A1 (en) 2018-05-11
US11007192B2 (en) 2021-05-18
US20190358227A1 (en) 2019-11-28
EP3534904B1 (en) 2022-03-16
DK3534904T3 (da) 2022-04-11
WO2018082814A1 (en) 2018-05-11
EP3534904A1 (en) 2019-09-11
ES2918548T3 (es) 2022-07-18

Similar Documents

Publication Publication Date Title
PL3534904T3 (pl) Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201819573D0 (en) Use of cannabinoids in the treatment of epilepsy
IL256501B (en) Causes, uses and methods of treating synuclein pathology
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
WO2016066744A3 (en) Gip agonist compounds and methods
GB2588261B (en) Apparatus, use of the apparatus and arrangement
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
SG11201607081RA (en) Massage chair and method of driving the same
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL265259A (en) Treatment of multiple sclerosis with chs-131
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
PL3322480T3 (pl) Bakterie Lactobacillus w leczeniu zaburzeń czynności serca
IL269681A (en) New methods for treating multiple sclerosis
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
EP3302456A4 (en) Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
HK40037135A (en) Use of hm4di in the treatment of seizure disorders